Xplus Inc. Logo

Xplus Inc.

IT consultancy guiding digital transformation via enterprise architecture & program management.

373200 | KO

Overview

Corporate Details

ISIN(s):
KR7373200005
LEI:
Country:
South Korea
Address:
서울특별시 송파구 송파대로 201 A동 13층, 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

XPLUS is a business and IT consultancy that assists companies in navigating digital transformation and future-proofing their operations. The firm's consultants specialize in enterprise architecture, IT architecture, and program management, helping clients realize their strategic goals by designing and building future-ready organizational structures. XPLUS leverages expertise in modern technologies such as business platforms, digital channels, and federated cloud solutions. The company's mission is to help businesses innovate, improve customer satisfaction, and reduce costs, enabling them to become market leaders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-25 00:00
Capital/Financing Update
전환가액의조정 (제5회차)
Korean 11.0 KB
2025-08-19 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 11.7 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.3 MB
2025-08-14 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 1.4 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-04 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 50.1 KB
2025-07-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 56.4 KB
2025-07-18 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 25.4 KB
2025-07-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 15.2 KB
2025-07-17 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-07-14 00:00
Share Issue/Capital Change
주요사항보고서(전환사채매수선택권행사자지정)
Korean 45.3 KB
2025-07-14 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 30.9 KB
2025-07-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 50.6 KB
2025-07-10 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 8.0 KB
2025-07-09 00:00
Capital/Financing Update
[기재정정]기타경영사항(자율공시) (제3회차 BW 취득후 재매각)
Korean 17.3 KB

Automate Your Workflow. Get a real-time feed of all Xplus Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Xplus Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Xplus Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

QUINSTREET, INC Logo
AI-driven marketplaces connecting consumers to brands in finance & home services on a pay-per-result basis.
United States of America
QNST
Qurient Co., Ltd. Logo
Biopharma developing novel drugs for cancer, inflammation, and infectious diseases.
South Korea
115180
Rafael Holdings, Inc. Logo
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
RaQualia Pharma Inc. Logo
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Recruit Holdings Co., Ltd. Logo
Global provider of HR tech (Indeed), staffing services, and business SaaS solutions.
Japan
6098
RELMADA THERAPEUTICS, INC. Logo
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
Renascience Inc. Logo
Develops innovative drugs and AI-powered medical devices for aging and hereditary diseases.
Japan
4889
Rentracks CO.,LTD. Logo
A pay-per-performance ad network with a closed ASP and comprehensive web consulting services.
Japan
6045
Replimune Group, Inc. Logo
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan
4978

Talk to a Data Expert

Have a question? We'll get back to you promptly.